Skip to the main content.

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

1 min read

October Image of the Month

YOU BE THE PATHOLOGIST!

What are these (*) large cells, considered to be one of the main inflammatory cells at the tissue-device interface? (Scale bar: 25 µm)

ANSWER

 

These are multinucleated giant cells!

 

Multinucleated giant cells are the dominant responders to biomaterial implantation. Other inflammatory cells can also be observed (lymphocytes, macrophages, plasma cells). The evaluation of cell type and severity of the inflammation are critical in assessment of local tolerance by medical device pathologists.

 

They are derived from « frustrated » macrophages which are unable to degrade a foreign body and so fuse to increase their phagocytosis ability. They are expected when foreign material is implanted, but some materials elicit an even greater multinucleated giant cell response than others. For example, sutures, such as are present in the field shown, are known to elicit a powerful inflammatory response.

 

H&ES, Original magnification: x40, scale bar: 25 μm.

*: Multinucleated giant cell

 

This histopathology image is one example from the comprehensive suite of Pathology Services offered by Veranex Preclinical Services’ in-house team of Veterinary Pathologists.

 

If you are interested in learning more about our preclinical research and pathology services, we encourage you to get in touch with us. We would be delighted to discuss your specific needs and plans.

 

Recent Study Co-authored by Veranex Staff Highlights Cost-effectiveness of Home Non-invasive Ventilation in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom

By developing a cost-effectiveness model and associated manuscript for home non-invasive ventilation in patients with persistent hypercapnia after...

Read More

Study by Veranex and Alcon Highlights Time Efficiencies for Femtosecond Laser-Assisted Cataract Surgery

Veranex’s Commercial Strategy team partnered with Alcon in 2020 to design and execute a time-and-motion study comparing Alcon’s femtosecond...

Read More

Addressing Inequity in Healthcare – A Case Study of Tackling Liver Cancer in New Zealand

The following article illustrates how inequities arise in healthcare, one disease at a time. It highlights insights from a program we are currently...

Read More